Society of Hematologic Oncology | Association Partnerships

According to Elisabetta Abruzzese, MD, PhD. balancing the care of the mother, the baby, as well disease burden is needed for patients with chronic myeloid leukemia who are pregnant.

Despite complete remission rates of up to 90%, late toxicities, such as secondary malignancies and cardiovascular events, are key concerns in patients treated for early-stage Hodgkin lymphoma.

Although chemotherapy has represented the standard therapeutic modality for indolent non-Hodgkin lymphoma, monoclonal antibodies, immunomodulatory agents, targeted agents, bispecific antibodies, and cellular therapies are now available.

In an interview, Brad S. Kahl, MD, discussed the changes in the field of follicular lymphoma and how physicians should approach treatment.

The diffuse large B-cell lymphoma treatment landscape is evolving with Pola-R-CHP and CAR T-cell therapy moving into the frontline setting.

Data points to the loss of predictive value of an interim PET2 scan for patients with Hodgkin lymphoma when treated with a regimen containing brentuximab vedotin.

Results from 2 studies shows ciltacabtagene autoleucel to prolong progression-free survival and induce response in patients with relapsed or refractory multiple myeloma.

Although it is well-established that MRD negativity plays an important prognostic role in Ph-positive ALL, the optimal method to assess MRD in this disease and how to use this information therapeutically are still being established.

Research now is addressing how subsequent therapies can meet needs of patients with Hodgkin lymphoma who progress after early lines of treatment.

Currently, there are few treatment options for patients with polycythemia vera that can help to control hematocrit levels and reduce the need for phlebotomy and the incidence of thrombosis.

Results from the phase 3 AGILE study presented at SOHO 2022 show that ivosidenib plus azacitidine prolong event-free and overall survival with good responses vs placebo in patients with IDH1-mutated acute myeloid leukemia

Jennifer R. Brown, MD, PhD, understands that the goal for patients with cancer requires the highest standards of care, but delivering on that goal is a complicated clinical challenge.

Disparities not only are widening among racial groups, but socioeconomic inequities should also be considered and addressed by the wider healthcare community, according to a lymphoma expert.

Early data have shown the promise of CD19-directed chimeric antigen receptor T cells for indolent lymphoma treatment, but longer follow-up is needed to determine if these responses represent cures in these historically difficult-to-treat malignancies.

CARTITUDE-1 update shows continued deep and durable response with iltacabtagene autoleucel in patients with heavily pretreated multiple myeloma.

Rituximab with bendamustine lead to superior outcomes compared with than 2 other popular triplet therapies in patients with treatment-naïve Waldenström macroglobulinemia.

Olatoyosi Sobulo Odenike, MD, explored the risk factors for evolution to MPN AP/blast phase, outcomes for current treatment methods, and potential targeted therapies during a presentation.

Multiple new targets are being researched for the treatment of chronic lymphocytic leukemia, and experts a particularly excited about novel BTK inhibitors and cellular therapies.

Controlling infection in patients with chronic lymphocytic leukemia who have an increased risk for infection, may be key for improving survival rates.

Data from the phase 1/2 BRUIN clinical trial showed a 62% objective response rate with responses increasing over time.

In the REVEAL study, having high-risk polycythemia vera was associated with lower survival at 4 years compared with low-risk disease.

Active phase 2 and 3 studies offer different concepts to the treatment myelofibrosis, according to Srdan Verstovsek, MD.

Adapting therapy to patients using the available criteria may be the key to future treatment in patients with polycythemia vera.

For patients with low-risk myelodysplastic syndrome, standardized treatment options are not readily available and dependent on the patient’s specific conditions.

According to David T. Teachey, MD, newly developed therapies have improved remission rates in T-ALL and B-ALL.

Nelson J. Chao, MD, discusses a shift at Duke Cancer Institute from in-office care to home care in patients undergoing hematopoietic stem cell transplantation for hematologic malignancies.

Experts who treat chronic graft-versus-host disease have not only learned to understand the pathophysiology of the disease but are also understanding how to implement new treatment modalities.

Targeted Oncology, a multimedia resource that offers content and expert opinions on standard and emerging treatments in the oncology field, announces the addition of the Society of Hematologic Oncology to its Strategic Alliance Partnership program.

Failure-free survival (FFS) for patients with follicular lymphoma has had a lack of improvement, fueling interest in new treatment strategies that may offer promise for better outcomes.

Single-agent ibrutinib (Imbruvica) data showed durable responses in patients with untreated or relapsed/refractory chronic lymphocytic leukemia (CLL).